Main focus

The laboratory physician and internist Dr. med. Beate Roxane Jaeger is head of the Lipid Center North Rhine in Germany (Wertgasse 35, 45468 Mülheim/Ruhr, Germany) and has been treating patients with the so-called H.E.L.P. -Apheresis (heparin-induced extracorporeal LDL/fibrinogen precipitation) for years with severe lipid metabolism disorders (therapy-refractory hypercholesterolemia) and resulting secondary diseases.

Beate R. Jaeger, MD, studied medicine in Essen, Germany and Zurich, Switzerland from 1986 to 1993. In 1994 she wrote her dissertation in endocrinology for her doctorate in medicine at the University of Essen with the topic “Thyroid Metabolism in Chronic Hemodialysis Patients” under the supervision of Prof. Dr. D. Reinwein with the rating “Magna cum laude”.

Since 1991, Dr. Jaeger’s scientific interest has focused on the pathobiochemistry of metabolic diseases and thus also on research into the causes of chronic and acute inflammatory processes of the endothelium. Endothelium is the inner skin of lymphatic and blood vessels. It represents a protective shield within the vessels that regulates the exchange of substances between tissue and blood. In addition, the endothelium adjusts various processes in the microvessels, such as the flowability of the blood, for example by inhibiting and activating coagulation processes.

Her clinical studies on the development and evolution of atherosclerosis, atherothrombosis, hemostasis and rheology have contributed to the development of new preventive and therapeutic strategies. In the meantime, Dr. Beate Jaeger has become an independent contact for questions concerning atherosclerosis and its treatment and therapy with H.E.L.P. -Apheresis (Heparin-induced Extracorporeal LDL/ Fibrinogen Precipitation.

To date, Dr. Beate R. Jaeger has published more than 50 scientific articles in journals including Lancet, Nature CP Cardio, NEJM or PLOS One. In 2009, she was awarded the Science Prize of the German Society of Nephrology.

Medical focus

  • Lipoprotein metabolic disorders (dyslipoproteinemias)
  • resulting atherosclerotic diseases (stroke, myocardial infarction)
  • disorders of primary (cellular) and secondary hemostasis (plasmatic blood coagulation)
  • Rheological disorders (microcirculatory disorders with increased risk of cerebrovascular complications such as peripheral arterial occlusive disease, myocardial infarction